港股异动 | 石药集团涨逾3% 附属研发的M802获美国FDA临床试验批准
格隆汇9月3日丨石药集团(1093.HK)现报16.6港元,涨3.75%,暂成交2.55亿港元,最新总市值1035亿港元。石药集团昨日盘后发布公告称,集团非全资附属公司武汉友芝友生物制药自主研发的注射用重组抗HER2和CD3人源化双特异性抗体(M802)获得美国食品药品监督管理局(FDA)批准在美国进行临床试验。M802为国内首个招募T细胞并靶向HER2阳性乳腺癌和胃癌等的双靶向特异性抗体,此次美国临床试验的批准将为友芝友生物开展创新药物国际合作和进军国际市场提供有力支持。此前美银美林升石药目标价至15.5港元,评级“中性”;中金则予石药“跑赢行业”评级,目标价18.2港元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.